CA2497873A1 - Nouvelles methodes de diagnostic et de therapie et reactifs correspondants - Google Patents

Nouvelles methodes de diagnostic et de therapie et reactifs correspondants Download PDF

Info

Publication number
CA2497873A1
CA2497873A1 CA002497873A CA2497873A CA2497873A1 CA 2497873 A1 CA2497873 A1 CA 2497873A1 CA 002497873 A CA002497873 A CA 002497873A CA 2497873 A CA2497873 A CA 2497873A CA 2497873 A1 CA2497873 A1 CA 2497873A1
Authority
CA
Canada
Prior art keywords
protein
edd
complex
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002497873A
Other languages
English (en)
Inventor
Colin Watts
Darren Saunders
Michelle Henderson
Jennifer Clancy
Susan Henshall
Robert Sutherland
Philippa O'brien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Garvan Institute of Medical Research
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2002951346A external-priority patent/AU2002951346A0/en
Application filed by Individual filed Critical Individual
Publication of CA2497873A1 publication Critical patent/CA2497873A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/9015—Ligases (6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte à de nouvelles méthodes de détection ou de traitement de la régulation aberrante du cycle cellulaire associée à l'expression d'une protéine nucléaire codée par un gène qui est lié pour mapper la position 8q22.3 du génome humain, ainsi qu'à de nouveaux réactifs utiles à cet effet. De manière plus particulière, cette invention concerne de nouvelles sondes d'acides nucléiques et de nouvelles sondes protéiques, qu'on utilise pour détecter un gène qui est lié pour mapper la position 8q22.3 du génome humain ou ses produits d'expression, ladite expression ou bien l'expression élevée dudit gène étant associée à l'aspect ou à l'existence de tumeurs associées au cancer, à la détérioration de l'ADN et aux effets induits sur les cellules par le récepteur de la progestérone. La présente invention concerne également des réactifs et des méthodes de détection ou de modulation des produits d'expression du gène, tel que, par exemple, dans le diagnostic ou le traitement du cancer, de la prolifération cellulaire, de la détérioration de l'ADN ou des effets induits sur les cellules par le récepteur de la progestérone.
CA002497873A 2002-09-05 2003-09-05 Nouvelles methodes de diagnostic et de therapie et reactifs correspondants Abandoned CA2497873A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2002951346A AU2002951346A0 (en) 2002-09-05 2002-09-05 Diagnosis of ovarian cancer
AU2002951346 2002-09-05
US42521802P 2002-11-07 2002-11-07
US60/425,218 2002-11-07
PCT/AU2003/001164 WO2004022750A1 (fr) 2002-09-05 2003-09-05 Nouvelles methodes de diagnostic et de therapie et reactifs correspondants

Publications (1)

Publication Number Publication Date
CA2497873A1 true CA2497873A1 (fr) 2004-03-18

Family

ID=31979115

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002497873A Abandoned CA2497873A1 (fr) 2002-09-05 2003-09-05 Nouvelles methodes de diagnostic et de therapie et reactifs correspondants

Country Status (4)

Country Link
EP (1) EP1539957A4 (fr)
JP (1) JP2005537790A (fr)
CA (1) CA2497873A1 (fr)
WO (1) WO2004022750A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200639252A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular hypertension targets
IL177006A0 (en) * 2005-08-02 2006-12-10 Veridex Llc Predicting bone relapse of breast cancer
JP2008297257A (ja) * 2007-05-31 2008-12-11 St Marianna Univ School Of Medicine 消化器癌の新規治療薬
CN101429540B (zh) * 2007-11-09 2013-07-10 北京雅康博生物科技有限公司 实时定量pcr检测细胞周期蛋白b2基因表达的方法
CN102559601B (zh) * 2012-01-13 2014-09-03 清华大学 用于鉴定肿瘤细胞或肿瘤组织的crept抗体
WO2014038524A1 (fr) * 2012-09-05 2014-03-13 和光純薬工業株式会社 Procédé de dépistage du cancer du sein

Also Published As

Publication number Publication date
EP1539957A1 (fr) 2005-06-15
WO2004022750A1 (fr) 2004-03-18
EP1539957A4 (fr) 2006-10-11
JP2005537790A (ja) 2005-12-15

Similar Documents

Publication Publication Date Title
US20060147922A1 (en) Novel diagnostic and therapeutic methods and reagents therefor
EP2518163B1 (fr) Modifications spécifiques du cancer de la prostate dans l'expression du gène ERG et procédés de détection sur la base de ces altérations
Wang et al. Sprouty4, a suppressor of tumor cell motility, is downregulated by DNA methylation in human prostate cancer
US6512102B1 (en) Compositions and methods of diagnosis and treatment using casein kinase I
US20050208486A1 (en) Brca-1 regulators and methods of use
US20040018525A1 (en) Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma
JP2004159640A5 (ja) 悪性腫瘍の予測、診断、予後判定、予防および治療のための方法および組成物
WO2013141266A1 (fr) Procédé pour détecter un nouveau corps fusionné ret
JP2007512807A (ja) 悪性腫瘍の処置に対する応答予測のための方法および組成物
EP1654383A1 (fr) Substances et methodes pour le depistage, le diagnostic et le traitement du cancer colorectal
JP2009165473A (ja) 癌
JP2008505307A (ja) ＨＡＵＳＰ−Ｍｄｍ２相互作用及びその使用
CA2497873A1 (fr) Nouvelles methodes de diagnostic et de therapie et reactifs correspondants
JP2006524492A (ja) 血管形成に関連する核酸分子を同定するための方法
US20140234321A1 (en) Hunk, a snf1-related kinase essential for mammary tumor metastasis
WO2013113942A2 (fr) Nouveaux gènes de fusion dans le cancer du poumon
US8029989B2 (en) Method using snail transcriptional repressor
AU2003257275A1 (en) Novel diagnostic and therapeutic methods and reagents therefor
US7964369B2 (en) Polypeptide complex that regulates cell cycle and anergy
WO2001055450A2 (fr) GENES AMPLIFIES EN 17q23
US20050181374A1 (en) Kruppel-like factor 6 ( KLF6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein
US20090238836A1 (en) Hip kinase for fertility control
US8241846B1 (en) Hedgehog pathway modulation and uses thereof for treating, preventing and/or diagnosing cancer
WO2008075713A1 (fr) Marqueur pour le diagnostic du cancer et molécule cible pour une thérapie
US8084434B2 (en) Runx2 isoforms in angiogenesis

Legal Events

Date Code Title Description
FZDE Discontinued